Physician profile

Lawrence Markovitz

Mc Lean, VA

NPI 1558390427

$18,175.53

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Long Term Medical Supply Or Device Loan$4,800.00
Food and Beverage$152.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Angiodynamics, INC. $17,788.42 2019-2023 Venacure 1470 Pro
Venclose INC. $109.97 2019
Cashflow Solutions, LLC $106.90 2023-2024 Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White
Bard Peripheral Vascular, INC. $53.23 2021
Medtronic Vascular, INC. $51.41 2019
Organogenesis INC. $45.35 2023 Puraply
Boston Scientific Corporation $20.25 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lawrence Markovitz

$18,175.53

in general payments reported 2019-2025

Years
2019-2024
Top company
Angiodynamics, INC.

https://glasscript.com/doctor/1294267/lawrence-markovitz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.